Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 4,628 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Dose Placebo Clear all

Conditions: COVID-19
Interventions: VYD2311-SD, VYD2311-MD, Placebo; Drug
Lead sponsor: Invivyd, Inc.; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 1,770 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 20
States / cities: Long Beach, California • San Diego, California • Orlando, Florida + 17 more

Conditions: Restless Legs Syndrome
Interventions: GEn 1200mg, Gen 6000 mg, GEn Placebo, Moxifloxacin Placebo, Moxifloxacin; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Tooth, Impacted, Tooth Diseases, Stomatognathic Diseases
Interventions: Ibuprofen 200Mg Oral Cap, Ibuprofen 200Mg Oral Tablet, Placebo Liquid Capsule, Placebo Tablets; Drug · Other
Lead sponsor: Reckitt Benckiser Healthcare (UK) Limited; Industry
Eligibility: 16 Years to 55 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Liver Fibrosis/NASH
Interventions: BMS-986171, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Chula Vista, California • Cypress, California

Conditions: Healthy Participants Study
Interventions: AZD0292, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obstructive Sleep Apnea
Interventions: AD182, AD504, Placebo, Polysomnography; Drug · Diagnostic Test
Lead sponsor: Apnimed; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Anterior Cruciate Ligament (ACL) Reconstruction
Interventions: Gabapentin; Other
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: 12 Years to 18 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Memory Impairment
Interventions: Sugar pill, Minocycline; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Postoperative Pain
Interventions: CR845, Placebo; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 18
States / cities: Florence, Alabama • Mobile, Alabama • Montgomery, Alabama + 14 more

Conditions: Healthy
Interventions: SRX251; Drug
Lead sponsor: Azevan Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Stroke
Interventions: duloxetine, Cyproheptadine, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Cardiovascular
Interventions: AMG 529, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 65
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more

Conditions: Diabetes Type 2
Interventions: Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 29
States / cities: Scottsdale, Arizona • Tucson, Arizona • Canoga Park, California + 25 more

Conditions: Rheumatoid Arthritis
Interventions: AMP-110, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Anniston, Alabama • Duncansville, Pennsylvania • Dallas, Texas

Conditions: Idiopathic Intracranial Hypertension (IIH)
Interventions: Tirzepatide, Tirzepatide Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV-1 Infection
Interventions: MVA.tHIVconsv3, MVA.tHIVconsv4, Placebo; Biological · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Major Depressive Disorder, Depression, Healthy
Interventions: SP-624, Placebo; Drug
Lead sponsor: Sirtsei Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Garden Grove, California • Lincoln, Nebraska

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Perampanel, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: HIV Prevention
Interventions: Tenofovir 1% vaginal gel, Depo-medroxyprogesterone acetate (DMPA), Oral contraceptive: LNG 150 mcg and EE 30 mcg; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Norfolk, Virginia

Conditions: Cocaine Dependence
Interventions: JDtic; Drug
Lead sponsor: RTI International; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Pain
Interventions: Acetaminophen/Naproxen Sodium Fixed Combination, Naproxen Sodium, Acetaminophen, Placebo; Drug
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 16 Years to 50 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Lymphocytic Leukemia
Interventions: Idelalisib, Bendamustine, Rituximab, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Fullerton, California • La Jolla, California • Santa Maria, California + 20 more

Conditions: Long QT Syndrome
Interventions: LQT-1213, Placebo, Dofetilide 250 μg Cap; Drug
Lead sponsor: Thryv Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: West Bend, Wisconsin

Search by objective public record fields.

Study of VYD2311 for the Prevention of COVID-19

A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers

Ibuprofen Liquid Capsules 2 x 200 mg Efficacy and PK/PD Study in Surgical Removal of Impacted Third Molars

A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea

Gabapentin Premedication for ACL Reconstruction: RCT

The Effects of Minocycline in Humans

Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery

Safety Study of SRX251 Capsules in Healthy Female Volunteers

Mechanisms of Neuromuscular Fatigue Post Stroke

AMG 529 First in Human Study

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis

Tirzepatide in Idiopathic Intracranial Hypertension Trial

Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults

A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression

Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

First in Humans Study of JDTic

A Study of an Acetaminophen/Naproxen Sodium Fixed Combination, Acetaminophen and Naproxen Sodium in Postoperative Dental Pain

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).